Literature DB >> 21498668

Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11.

Amanda Waddell1, Richard Ahrens, Kris Steinbrecher, Burke Donovan, Marc E Rothenberg, Ariel Munitz, Simon P Hogan.   

Abstract

Recent genome-wide association studies of pediatric inflammatory bowel disease have implicated the 17q12 loci, which contains the eosinophil-specific chemokine gene CCL11, with early-onset inflammatory bowel disease susceptibility. In the current study, we employed a murine model of experimental colitis to define the molecular pathways that regulate CCL11 expression in the chronic intestinal inflammation and pathophysiology of experimental colitis. Bone marrow chimera experiments showed that hematopoietic cell-derived CCL11 is sufficient for CCL11-mediated colonic eosinophilic inflammation. We show that dextran sodium sulfate (DSS) treatment promotes the recruitment of F4/80(+)CD11b(+)CCR2(+)Ly6C(high) inflammatory monocytes into the colon. F4/80(+)CD11b(+)CCR2(+)Ly6C(high) monocytes express CCL11, and their recruitment positively correlated with colonic eosinophilic inflammation. Phenotypic analysis of purified Ly6C(high) intestinal inflammatory macrophages revealed that these cells express both M1- and M2-associated genes, including Il6, Ccl4, Cxcl2, Arg1, Chi3l3, Ccl11, and Il10, respectively. Attenuation of DSS-induced F4/80(+)CD11b(+)CCR2(+)Ly6C(high) monocyte recruitment to the colon in CCR2(-/-) mice was associated with decreased colonic CCL11 expression, eosinophilic inflammation, and DSS-induced histopathology. These studies identify a mechanism for DSS-induced colonic eosinophilia mediated by Ly6C(high)CCR2(+) inflammatory monocyte/macrophage-derived CCL11.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498668      PMCID: PMC3423906          DOI: 10.4049/jimmunol.1003844

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  Activated eosinophils in inflammatory bowel disease: do they matter?

Authors:  P Desreumaux; S Nutten; J F Colombel
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

2.  Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease.

Authors:  S C Bischoff; J Mayer; Q T Nguyen; M Stolte; M P Manns
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

Review 3.  Chemokines: a new classification system and their role in immunity.

Authors:  A Zlotnik; O Yoshie
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

4.  Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-beta in macrophages that have ingested apoptotic cells.

Authors:  P P McDonald; V A Fadok; D Bratton; P M Henson
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

5.  Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics.

Authors:  S Ying; Q Meng; K Zeibecoglou; D S Robinson; A Macfarlane; M Humbert; A B Kay
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

6.  A critical role for eotaxin in experimental oral antigen-induced eosinophilic gastrointestinal allergy.

Authors:  S P Hogan; A Mishra; E B Brandt; P S Foster; M E Rothenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

7.  Murine eotaxin-2: a constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression.

Authors:  N Zimmermann; S P Hogan; A Mishra; E B Brandt; T R Bodette; S M Pope; F D Finkelman; M E Rothenberg
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

8.  Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease.

Authors:  O Saitoh; K Kojima; K Sugi; R Matsuse; K Uchida; K Tabata; K Nakagawa; M Kayazawa; I Hirata; K Katsu
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

9.  CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis.

Authors:  Steven Maltby; Carolin Wohlfarth; Matthew Gold; Lori Zbytnuik; Michael R Hughes; Kelly M McNagny
Journal:  Am J Pathol       Date:  2010-08-09       Impact factor: 4.307

10.  Dextran sulphate sodium-induced colitis is ameliorated in interleukin 4 deficient mice.

Authors:  L Stevceva; P Pavli; A Husband; A Ramsay; W F Doe
Journal:  Genes Immun       Date:  2001-10       Impact factor: 2.676

View more
  61 in total

1.  Selective upregulation of microRNA expression in peripheral blood leukocytes in IL-10-/- mice precedes expression in the colon.

Authors:  Jeremy S Schaefer; Dina Montufar-Solis; Nadarajah Vigneswaran; John R Klein
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

2.  Amyloid precursor protein expression modulates intestine immune phenotype.

Authors:  Kendra L Puig; Adam J Swigost; Xudong Zhou; Mary Ann Sens; Colin K Combs
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-29       Impact factor: 4.147

Review 3.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

4.  Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis.

Authors:  Ning Lu; Lihong Wang; Hailong Cao; Liping Liu; Luc Van Kaer; Mary K Washington; Michael J Rosen; Philip E Dubé; Keith T Wilson; Xiubao Ren; Xishan Hao; D Brent Polk; Fang Yan
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

5.  CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.

Authors:  Maria Lampinen; Amanda Waddell; Richard Ahrens; Marie Carlson; Simon P Hogan
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

6.  A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation.

Authors:  Rose A Whelan; Sebastian Rausch; Friederike Ebner; Dorothee Günzel; Jan F Richter; Nina A Hering; Jörg-Dieter Schulzke; Anja A Kühl; Ahmed Keles; Pawel Janczyk; Karsten Nöckler; Lothar H Wieler; Susanne Hartmann
Journal:  Mol Ther       Date:  2014-07-02       Impact factor: 11.454

7.  Epithelial Expression of an Interstitial Lung Disease-Associated Mutation in Surfactant Protein-C Modulates Recruitment and Activation of Key Myeloid Cell Populations in Mice.

Authors:  Alessandro Venosa; Jeremy Katzen; Yaniv Tomer; Meghan Kopp; Sarita Jamil; Scott J Russo; Surafel Mulugeta; Michael F Beers
Journal:  J Immunol       Date:  2019-03-25       Impact factor: 5.422

Review 8.  Biological Modulators in Eosinophilic Diseases.

Authors:  Panida Sriaroon; Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

9.  G2A Signaling Dampens Colitic Inflammation via Production of IFN-γ.

Authors:  S Courtney Frasch; Eóin N McNamee; Douglas Kominsky; Paul Jedlicka; Claudia Jakubzick; Karin Zemski Berry; Matthias Mack; Glenn T Furuta; James J Lee; Peter M Henson; Sean P Colgan; Donna L Bratton
Journal:  J Immunol       Date:  2016-07-08       Impact factor: 5.422

10.  Therapeutic inflammatory monocyte modulation using immune-modifying microparticles.

Authors:  Daniel R Getts; Rachael L Terry; Meghann Teague Getts; Celine Deffrasnes; Marcus Müller; Caryn van Vreden; Thomas M Ashhurst; Belal Chami; Derrick McCarthy; Huiling Wu; Jin Ma; Aaron Martin; Lonnie D Shae; Paul Witting; Geoffrey S Kansas; Joachim Kühn; Wali Hafezi; Iain L Campbell; David Reilly; Jana Say; Louise Brown; Melanie Y White; Stuart J Cordwell; Steven J Chadban; Edward B Thorp; Shisan Bao; Stephen D Miller; Nicholas J C King
Journal:  Sci Transl Med       Date:  2014-01-15       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.